Vaxart(VXRT) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart's oral pill vaccine candidate to protect or reduce the ef ect of the disease in infants "We are excited about the potential for our oral pill vaccine technology, not only for the Company but for the benefit of society. We believe the data we have generated to date are compelling and demonstrate our vaccines' potentia ...